Company / Shareholders' Equity
Dianthus Therapeutics, Inc. /DE/ Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$493.4M
FY2025
5-year range
-$44.4M / $493.4M
FY2021-FY2025
Trend
+192.2%
vs FY2024
Sector context
#95 of 213
Health Care
What the data says
At $493M, Dianthus Therapeutics, Inc. /DE/'s shareholders' equity ranks #95 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from -$44M in FY2022 to $493M in FY2025.
Based on SEC 10-K filings.
$493M in FY2025 with a 5-year CAGR of +27.9%.
Improved from $169M to $493M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +27.9%
- 10-Year CAGR
- -
Sector benchmark
#95 of 213 in Health CareTop 45% of 213This company $493.4M Sector average $2.5B
▼
-80.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.9%, indicating consistent growth.
- In FY2025, shareholders' equity increased 192.2% year-over-year.
- Ranks #95 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $493.4M | +192.2% |
| FY2024 | $168.9M | +0.0% |
| FY2023 | $168.9M | +480.6% |
| FY2022 | -$44.4M | -157.2% |
| FY2021 | -$17.2M | -112.0% |
| FY2020 | $143.9M | +1.9% |
| FY2019 | $141.2M | -3.1% |
| FY2018 | $145.6M | +445.8% |
| FY2017 | -$42.1M | -374.6% |
| FY2016 | -$8.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026